- Home
- EVAX vs VRAX Comparison
EVAX vs VRAX Comparison
Compare EVAX & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- VRAX
- Stock Information
- Founded
- EVAX 2008
- VRAX 2013
- Country
- EVAX Denmark
- VRAX United Kingdom
- Employees
- EVAX N/A
- VRAX N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- EVAX Health Care
- VRAX Health Care
- Exchange
- EVAX Nasdaq
- VRAX Nasdaq
- Market Cap
- EVAX 8.7M
- VRAX 7.8M
- IPO Year
- EVAX 2021
- VRAX 2022
- Fundamental
- Price
- EVAX $0.89
- VRAX $1.98
- Analyst Decision
- EVAX Strong Buy
- VRAX
- Analyst Count
- EVAX 2
- VRAX 0
- Target Price
- EVAX $11.00
- VRAX N/A
- AVG Volume (30 Days)
- EVAX 82.5K
- VRAX 369.4K
- Earning Date
- EVAX 10-31-2024
- VRAX 02-05-2025
- Dividend Yield
- EVAX N/A
- VRAX N/A
- EPS Growth
- EVAX N/A
- VRAX N/A
- EPS
- EVAX N/A
- VRAX N/A
- Revenue
- EVAX $3,295,000.00
- VRAX $84,872.00
- Revenue This Year
- EVAX $4,845.21
- VRAX $5,169.18
- Revenue Next Year
- EVAX $30.30
- VRAX $66.97
- P/E Ratio
- EVAX N/A
- VRAX N/A
- Revenue Growth
- EVAX N/A
- VRAX 7.03
- 52 Week Low
- EVAX $0.85
- VRAX $0.60
- 52 Week High
- EVAX $13.61
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- EVAX 21.83
- VRAX 47.15
- Support Level
- EVAX $0.85
- VRAX $1.51
- Resistance Level
- EVAX $0.96
- VRAX $2.38
- Average True Range (ATR)
- EVAX 0.15
- VRAX 0.21
- MACD
- EVAX -0.00
- VRAX 0.01
- Stochastic Oscillator
- EVAX 5.75
- VRAX 27.83
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.